UBS on Seattle Genetics

Loading...
Loading...
In a research note released Wednesday, UBS analyst Matthew Roden Upgraded Seattle Genetics, Inc.
SGEN
to Buy from Neutral and is maintaining a price target of $48.00. The analyst said that they have made the upgrade based on two primary reasons. The first being the stock's underperformance this year due to increased speculation in regards to the phase-3 data expected. The second reason is the analyst believes that the proprietary pipeline development is not reflected in the stock. The analyst continued to say that fear over AETHERA may be overstated and ultimately believes that upside will be driven by the pipeline.
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidance
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...